IHAM
KURA icon

Integral Health Asset Management’s Kura Oncology KURA Stock Holding History

Integral Health Asset Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$2.06M – 86
2024
Q2 		$2.06M Buy
+100,000
New +$2.06M 0.2% 71
2022
Q4 		– Sell
-500,000
Closed -$6.83M – 79
2022
Q3 		$6.83M Buy
500,000
+38,690
+8% +$597K 1.33% 31
2022
Q2 		$8.46M Buy
461,310
+124,310
+37% +$1.79M 1.74% 20
2022
Q1 		$5.42M Buy
337,000
+252,000
+296% +$3.64M 1.41% 30
2021
Q4 		$1.19M Buy
85,000
+25,000
+42% +$405K 0.33% 62
2021
Q3 		$1.12M Sell
60,000
-10,000
-14% -$188K 0.32% 64
2021
Q2 		$1.46M Buy
70,000
+10,000
+17% +$248K 0.4% 62
2021
Q1 		$1.7M Sell
60,000
-35,000
-37% -$1.11M 0.48% 56
2020
Q4 		$3.1M Buy
95,000
+45,000
+90% +$1.58M 0.92% 39
2020
Q3 		$1.53M Buy
+50,000
New +$1.1M 0.47% 62

Other funds holding KURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Integral Health Asset Management's KURA Position: Q3 2024 in Review

Integral Health Asset Management sold out of Kura Oncology (KURA) in Q3 2024, closing a stake of 100,000 shares — an estimated $2.06M sold.

Integral Health Asset Management first reported a position in KURA in Q3 2020 and held it in 10 quarters. The position peaked at $8.46M in Q2 2022. 179 funds tracked by Wall St. Rank hold KURA as of Q3 2024.

  • Integral Health Asset Management reported no remaining Kura Oncology position as of Q3 2024 after selling out during the quarter.
  • Integral Health Asset Management sold 100,000 Kura Oncology shares in Q3 2024, an estimated $2.06M.
  • Integral Health Asset Management first reported a position in Kura Oncology in Q3 2020 and held it in 10 quarters.
  • Integral Health Asset Management's Kura Oncology position peaked at $8.46M in Q2 2022.
  • 179 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2024.

Based on Integral Health Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.